Abstract
Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.
Method: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included. Results: Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata. Conclusion: JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.Keywords: Tofacitinib, CP690550, protein kinase inhibitor, JAK/STAT pathway, small molecule, psoriasis, alopecia areata, vitiligo.
Current Medicinal Chemistry
Title:Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Volume: 24 Issue: 11
Author(s): Kresimir Kostovic*, Sandra J. Gulin, Zrinka B. Mokos and Romana Ceovic
Affiliation:
- Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb,Croatia
Keywords: Tofacitinib, CP690550, protein kinase inhibitor, JAK/STAT pathway, small molecule, psoriasis, alopecia areata, vitiligo.
Abstract: Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.
Method: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included. Results: Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata. Conclusion: JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.Export Options
About this article
Cite this article as:
Kostovic Kresimir*, Gulin J. Sandra, Mokos B. Zrinka and Ceovic Romana, Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology, Current Medicinal Chemistry 2017; 24 (11) . https://dx.doi.org/10.2174/1874467210666170113104503
DOI https://dx.doi.org/10.2174/1874467210666170113104503 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction
Current Vascular Pharmacology TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters Small Molecules Modulating Biogenesis or Processing of microRNAs with Therapeutic Potentials
Current Medicinal Chemistry Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Vitamin D Deficiency May Be Associated with a More Rapid Decline in CD4 Cell Count to <350 Cells/µL in Untreated HIV-Infected Adults
Current HIV Research Itraconazole Induced Congestive Heart Failure, A Case Study
Current Drug Safety Managing the Liabilities Arising from Structural Alerts: A Safe Philosophy for Medicinal Chemists
Current Medicinal Chemistry Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery